Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus Nab-Paclitaxel in Advanced Bladder Cancer
NCT06009848Phase 2Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in bladder cancer, sponsored by The Second Hospital of Tianjin Medical University. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT06009848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06009848.